SE470273B - Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer - Google Patents

Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Info

Publication number
SE470273B
SE470273B SE9003025A SE9003025A SE470273B SE 470273 B SE470273 B SE 470273B SE 9003025 A SE9003025 A SE 9003025A SE 9003025 A SE9003025 A SE 9003025A SE 470273 B SE470273 B SE 470273B
Authority
SE
Sweden
Prior art keywords
cytokeratin
fragments
cytokeratins
digestion
monoclonal antibodies
Prior art date
Application number
SE9003025A
Other languages
English (en)
Swedish (sv)
Other versions
SE9003025D0 (sv
SE9003025L (sv
Inventor
B Wiklund
Aa Silen
Original Assignee
Idl Immunodeveloplab Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idl Immunodeveloplab Ab filed Critical Idl Immunodeveloplab Ab
Priority to SE9003025A priority Critical patent/SE470273B/sv
Publication of SE9003025D0 publication Critical patent/SE9003025D0/xx
Priority to EP91917180A priority patent/EP0550561B1/de
Priority to DE69132122T priority patent/DE69132122T2/de
Priority to JP51612591A priority patent/JP3210666B2/ja
Priority to AU85463/91A priority patent/AU8546391A/en
Priority to US08/030,100 priority patent/US5728537A/en
Priority to PCT/SE1991/000638 priority patent/WO1992005197A1/en
Priority to AT91917180T priority patent/ATE191921T1/de
Publication of SE9003025L publication Critical patent/SE9003025L/
Publication of SE470273B publication Critical patent/SE470273B/sv
Priority to US08/666,835 priority patent/US5780032A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9003025A 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer SE470273B (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
AT91917180T ATE191921T1 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten
AU85463/91A AU8546391A (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments
DE69132122T DE69132122T2 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten
JP51612591A JP3210666B2 (ja) 1990-09-24 1991-09-24 サイトケラチン断片の精製
EP91917180A EP0550561B1 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten
US08/030,100 US5728537A (en) 1990-09-24 1991-09-24 Methods of producing antibodies against cytokeraton fragments and test kits containing such fragments
PCT/SE1991/000638 WO1992005197A1 (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments
US08/666,835 US5780032A (en) 1990-09-24 1996-06-19 Method of using monoclonal antibodies to cytokeratin fragments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Publications (3)

Publication Number Publication Date
SE9003025D0 SE9003025D0 (sv) 1990-09-24
SE9003025L SE9003025L (sv) 1992-03-25
SE470273B true SE470273B (sv) 1993-12-20

Family

ID=20380430

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Country Status (8)

Country Link
US (2) US5728537A (de)
EP (1) EP0550561B1 (de)
JP (1) JP3210666B2 (de)
AT (1) ATE191921T1 (de)
AU (1) AU8546391A (de)
DE (1) DE69132122T2 (de)
SE (1) SE470273B (de)
WO (1) WO1992005197A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
ES2116906B1 (es) * 1996-03-28 1999-03-01 Consejo Superior Investigacion Anticuerpo monocional pc2.27 asociado a tumores.
US6890311B2 (en) 1997-09-16 2005-05-10 The Regents Of The University Of California Methods for performing medical procedures within a breast duct
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
WO1999016789A1 (en) * 1997-09-30 1999-04-08 Peviva Ab Apoptosis-related compounds and their use
ES2274781T3 (es) * 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
US20020122791A1 (en) * 2000-12-21 2002-09-05 Nicolette Charles A. Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
EP1698899A4 (de) * 2003-10-30 2007-05-23 Sysmex Corp Diagnostikum für uterusdrüsenkrebs und verfahren zum nachweis einer drüsenkrebszelle
EP2041299A4 (de) * 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
KR101292163B1 (ko) 2010-11-23 2013-08-12 한양대학교 산학협력단 Ｋｒｔ１９ 항체를 포함하는 항암용 조성물
SE538211C2 (sv) * 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2723203B2 (ja) * 1984-01-06 1998-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア サイトケラチン腫瘍マーカー及びそれらの検出のためのアッセイ
US4727021A (en) * 1984-06-01 1988-02-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cytokeratin
US4722895A (en) * 1984-09-25 1988-02-02 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Synthetic peptides for the production of specific keratin protein antibodies
DE3815932A1 (de) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh Verfahren zur identifizierung des ursprungs einer zellgewebsprobe
EP0267355B1 (de) * 1986-11-10 1991-09-18 PROGEN Biotechnik GmbH Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine
LU86654A1 (de) * 1986-11-10 1988-06-13 Progen Biotechnik Gmbh Verfahren und vorrichtung zum auffinden von zellaesionen
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados

Also Published As

Publication number Publication date
JPH06501469A (ja) 1994-02-17
DE69132122T2 (de) 2001-01-11
US5728537A (en) 1998-03-17
EP0550561B1 (de) 2000-04-19
SE9003025D0 (sv) 1990-09-24
DE69132122D1 (de) 2000-05-25
AU8546391A (en) 1992-04-15
ATE191921T1 (de) 2000-05-15
EP0550561A1 (de) 1993-07-14
JP3210666B2 (ja) 2001-09-17
WO1992005197A1 (en) 1992-04-02
US5780032A (en) 1998-07-14
SE9003025L (sv) 1992-03-25

Similar Documents

Publication Publication Date Title
SE470273B (sv) Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
AU606605B2 (en) Monoclonal antibodies to unreduced, nonenzymatically- glycated proteins
JPS60501309A (ja) 非小細胞肺癌に対する単クロ−ン抗体
US5500347A (en) Method for the purification of cytokeratin 20 and its use for the production of antibodies
US12304937B2 (en) Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof
Woodard et al. Characterization of epitopes of human secretory component on free secretory component, secretory IgA, and membrane-associated secretory component.
CA2088354C (en) Pancreas-elastasis-1-specific antibody, a process for obtaining it and a test kit containing such antibodies
KR101777254B1 (ko) En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
US11827696B2 (en) Antibody composition specifically recognizing an immunogenic fragment peptide of EN2 protein
AU618209B2 (en) Antigen recognized by mca 16-88
Perez et al. Bovine Reissner’s fiber (RF) and the central canal of the spinal cord: an immunocytochemical study using a set of monoclonal antibodies against the RF-glycoproteins
EP0145373A2 (de) Reinigung eines krebsassoziierten Proteins und Herstellung eines Antikörpers dazu
Jie et al. Monoclonal antibodies to GFAP epitopes available in formaldehyde fixed tissue
KR100493932B1 (ko) 레지스틴에 대한 단클론 항체, 이의 제조 방법, 및 용도
JPH0949836A (ja) 抗体による蛋白質構造の評価方法
EP0242727B1 (de) Verfahren zur Bestimmung von Adenocarcinoma-Antigenen
JPH0614041B2 (ja) 肺表面活性物質の検出方法及びそれに用いる試薬キツト
KR20110009604A (ko) Ｐｓａ를 인지하는 단클론 항체 및 이의 용도
Mochizuki et al. An immunoenzymometric assay for a CA 125‐like antigen, CA602
JPH0661276B2 (ja) 腫瘍関連抗原に特異的な抗体およびこれを利用する抗原の測定法
HK40019693A (en) Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same
JP2000065829A (ja) スタニオカルシンに対する抗体
JP2005143504A (ja) 抗体およびその用途
JPH08231600A (ja) 抗チロシナーゼモノクローナル抗体Ｆ（ａｂ’）２フラグメント
JPH08231599A (ja) 抗チロシナーゼモノクローナル抗体Ｆａｂフラグメント

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 9003025-5

Format of ref document f/p: F

NUG Patent has lapsed